경피 에스트라디올 패치

雌激素 A

经皮雌二醇贴片

Estradiol Transdermal Patch

Transdermal

Transdermal patches are universally recognized by clinical evidence as the safest method of estradiol administration. Because the estradiol absorbs through the skin directly into the bloodstream, it entirely bypasses liver first-pass metabolism, meaning its VTE (blood clot) risk profile is statistically identical to that of non-users.

Pharmacology

Bypassing First-Pass Metabolism

When you swallow oral estradiol, it hits your gastrointestinal tract and then travels directly to your liver (First-Pass Metabolism). This process:

• Forces the liver to ramp up synthesis of coagulation (clotting) factors, driving up VTE risk.
• Destroys ~95% of the drug, plummeting bioavailability.
• Alters lipid/cholesterol metabolism.

Patches deliver estradiol through the skin straight into the systemic circulation, completely circumventing liver first-pass metabolism ^[1] . This means:

• Negligible impact on liver coagulation factors.
• Highly stable and superior bioavailability.
• Gentle on the liver and lipid profile.

VTE (Blood Clot) Risk Data

Transdermal patches boast the lowest VTE risk of any estradiol administration method ^[2] :

Route	Relative Risk (RR)	95% CI
Transdermal Patch	0.97	0.79 - 1.19
Oral Estradiol	1.48	1.27 - 1.72

An RR ≈ 0.97 functionally means that utilizing transdermal patches carries no statistically significant increase in VTE risk compared to individuals not taking estrogen therapy at all ^[2] . This cements the patch as the mandatory first choice for anyone with preexisting clotting risk factors.

Blood Concentration Profile

• Reaches steady-state blood concentrations roughly 12-24 hours after application.
• Maintains incredibly flat, stable E2 levels for the duration of the patch’s lifecycle.
• Utterly avoids the aggressive peak-and-trough rollercoasters associated with oral, sublingual, or injectable routes.

Dosage Recommendations

These dosage ranges align with Endocrine Society 2017 Guidelines ^[3] and WPATH SOC 8 ^[4] :

Stage	Dose	Target E2 (pg/mL)	Timeline
Low Dose Start	50-100 µg/day	50-100	Months 1-6
Moderate Titration	100-200 µg/day	100-200	Months 6-12
Maintenance Phase	100-200 µg/day	100-200	12 Months+
Monotherapy (If no blockers)	200-400 µg/day	200-300	Only if bypassing T-blockers

The Typical Maximum

The standard maximum dose is 400 µg/day, historically utilized only if attempting monotherapy (suppressing T without anti-androgens). The vast majority of users hit their target clinical E2 range (100-200 pg/mL) at 100-200 µg/day ^[3] . Pushing E2 past 200 pg/mL will not feminize you faster; it only amplifies health risks.

How to Use Them

Application Sites

• Recommended: Lower abdomen, upper buttocks, outer thighs.
• Avoid: The breast area (prolonged localized E2 concentration is a severe breast cancer risk), joints, or areas where tight waistbands rub.
• Rotate: Never apply a new patch to the exact same spot as the old one to prevent contact dermatitis.

Replacement Frequency

Track Your Wear Time

Most patches are designed to be changed either every 3.5 days (twice a week) or every 7 days (once a week), depending on the specific brand. Follow the manufacturer’s timetable ruthlessly. Missing a replacement will cause your E2 to crash, triggering hot flashes and mood swings. Set phone alarms.

Practical Tips

• Apply only to clean, bone-dry skin. Do not construct your patches over lotions, oils, or freshly shaved wet skin.
• Press the patch firmly with the palm of your hand for 10 full seconds to heat-activate the adhesive.
• Normal showering and swimming are fine, but long, scalding hot baths may loosen the adhesive and dump the medication into your system prematurely.
• If a patch falls off, try to stick it back on; if it won’t hold, apply a new one immediately.

Target Audience

Transdermal Patches are heavily recommended for ^{[3] [4]} :

• Everyone (Patches are the gold standard for safety across the board).
• Users with VTE Risk Factors (BMI >30, Age >40, smokers, VTE family history) — Patches are non-negotiable here.
• Users taking CPA — CPA is inherently pro-coagulant; using patches prevents stacking clot risks.
• Users with Liver Abnormalities — Bypassing the liver drastically reduces metabolic burden.

Global Supply Realities

While medically superior, patches suffer from global logistical challenges:

• Cost: Without robust insurance or national healthcare, patches are astronomically more expensive out-of-pocket than oral pills.
• Shortages: Global supply chains for brands like Estradot or Climara frequently collapse, resulting in months-long regional shortages in the UK, EU, and Australia.
• If patches are utterly inaccessible to you, oral administration is a viable fallback—provided you have no preexisting VTE risks.

Common Brands

Brand	Specification	Replacement Cycle	Region
Climara	Releases 50 / 100 µg/day	Every 7 Days	US / EU / Global
Estradot	Releases 25-100 µg/day	Every 3.5 Days	UK / EU / AUS
Vivelle-Dot	Releases 25-100 µg/day	Every 3.5 Days	US
Estrana Tape	Releases 50 µg/day	Every 2 Days	Japan (Common in Asian DIY)

Monitoring Advice

• When to draw blood: 12-24 hours before your next patch change (measuring the trough level) ^[5] .
• Targets: E2 100-200 pg/mL, T < 50 ng/dL.

品牌图鉴

🇩🇪德国

Climara

厂商

拜耳 (Bayer)

规格

50µg/24h · 100µg/24h

外观

透明椭圆形薄膜贴片

每周更换一次，储库型贴片

🇨🇭瑞士

Estradot

厂商

Novartis

规格

25/37.5/50/75/100µg/24h

外观

小型透明圆形贴片

每周更换两次（每3-4天），基质型贴片

🇺🇸美国

Estraderm

厂商

Novartis

规格

50µg/24h · 100µg/24h

外观

透明圆形贴片

早期储库型贴片，部分地区已被 Estradot 替代

전체 브랜드 색인 보기 →